Genitourinary Cancers Articles

EU Panel Backs Avelumab/Axitinib Combo for Frontline RCC
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend approval of the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma. 
Choueiri Pushes for Discussion and Collaboration in Kidney Cancer
Toni Choueiri, MD, discusses the rationale behind the Kidney Cancer Research Summit and recent advances in the renal cell carcinoma landscape.
FDA Grants Enfortumab Vedotin Priority Review for Urothelial Cancer
The FDA has granted a priority review designation to a biologics license application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.
Updated OS Data Reported With Tivozanib in Highly Refractory Metastatic RCC
Results from the second prespecified analysis of the TIVO-3 trial showed a hazard ratio for overall survival of 0.99 for tivozanib compared with sorafenib in patients with highly refractory metastatic renal cell carcinoma. 
Novel Immunotherapy Combos Shake Up Bladder Cancer Paradigm
Petros Grivas, MD, highlights the evolving role of immunotherapy in bladder cancer and ongoing research slated to further progress along.
Pembrolizumab/Axitinib Combo Approved in Europe for Frontline RCC
The European Commission has approved the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma.
Ilixadencel Plus Sunitinib Induces Complete Responses in Metastatic RCC
The combination of the off-the-shelf cancer immune primer ilixadencel and sunitinib elicited a 11% complete response rate in patients with metastatic renal cell carcinoma, according to topline findings from the phase II MERECA trial (NCT02432846).
Precision Medicine to Take Hold in Advanced Bladder Cancer
Parminder Singh, MD, discusses ongoing research in advanced urothelial cancer and the focus on incorporating precision medicine in the field.
Clearing Up Confusion on Cytoreductive Nephrectomy in mRCC
David D. Thiel, MD, provides perspective on the CARMENA findings in metastatic renal cell carcinoma.
New and Emerging Immunotherapy Combos for Advanced RCC: Finding the Right Treatments
Emerging immunotherapy combinations have offered a strong challenge to sunitinib (Sutent) in the setting of frontline advanced clear cell renal cell carcinoma.
Publication Bottom Border
Border Publication
x